Johnson & Johnson (JNJ) Work In Process (2012 - 2018)
Johnson & Johnson's (JNJ) quarterly Work In Process came in at $2.1 billion in Q4 2018, down 8.98% year-on-year from $2.3 billion in Q4 2017, and up 6.19% quarter-over-quarter from $2.0 billion in Q3 2018.
Johnson & Johnson (JNJ) Work In Process (2012 - 2018) Analysis & Trends
Johnson & Johnson has disclosed Work In Process across 6 years of filings, most recently posting $2.1 billion for Q4 2018.
- Work In Process for Q4 2018 came in at $2.1 billion, down 8.98% year-over-year; the trailing twelve-month figure through Dec 2018 was $2.1 billion (down 8.98% YoY), and the FY2018 annual result was $2.1 billion, down 8.98% from the prior year.
- Work In Process came in at $2.1 billion for Q4 2018 at Johnson & Johnson, up from $2.0 billion in the prior quarter.
- In the past five years, Work In Process ranged from a high of $2.5 billion in Q4 2014 to a low of $2.0 billion in Q3 2018.
- The 4-year median for Work In Process is $2.2 billion (2016), against an average of $2.2 billion.
- Across the five-year window, Work In Process rose 6.04% in 2017 and decreased 8.98% in 2018, its largest moves.
- Johnson & Johnson's Work In Process stood at $2.5 billion in 2014, then decreased by 8.94% to $2.2 billion in 2016, then increased by 3.39% to $2.3 billion in 2017, then declined by 8.98% to $2.1 billion in 2018.
- The last three Work In Process figures came in at $2.1 billion (Q4 2018), $2.0 billion (Q3 2018), and $2.3 billion (Q3 2018), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 30, 2018 | 2.11 Bn |
| Sep 30, 2018 | 1.99 Bn |
| Jul 1, 2018 | 2.28 Bn |
| Dec 31, 2017 | 2.32 Bn |
| Jan 1, 2017 | 2.19 Bn |
| Jan 3, 2016 | 2.24 Bn |
| Dec 28, 2014 | 2.46 Bn |
| Dec 29, 2013 | 2.61 Bn |
| Dec 30, 2012 | 2.26 Bn |
| Jan 1, 2012 | 1.64 Bn |